Homocysteine and cerebrovascular disease;Homocisteína y enfermedad cerebrovascular

Revista de Neurologia

Volumn 38, Issue 4, 2004, Pages 347-358

  Sepulveda Sanchez, Juan M ^a,b   Matia Frances R ^a   Martinez Salio A ^a   Gonzalez De La Aleja Tejera J ^a   Rodriguez Pena Marin, M ^a   Porta Etessam, J ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b NONE   (Spain)

Author keywords

Cardiovascular disease; Carotid stenosis; Cerebrovascular disease; Homocysteine; Risk factors; Stroke

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; COLESTIPOL; COLESTYRAMINE; CYANOCOBALAMIN; CYCLOSPORIN A; FOLIC ACID; HOMOCYSTEINE; METHOTREXATE; NICOTINIC ACID DERIVATIVE; PYRIDOXINE; THEOPHYLLINE DERIVATIVE; TRIMETHOPRIM;

ATHEROSCLEROSIS; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; DOSE RESPONSE; EARLY DIAGNOSIS; FEMALE; HUMAN; HYPOTHESIS; MALE; METABOLIC REGULATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM; VASCULAR DISEASE;

EID: 1842612578     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3804.2003605     Document Type: Review

References (93)

1. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114: 473.
2. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386.
3. Uelan PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39: 1764-79.
4. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. NEJM 1998; 338: 1042-50.
5. Kang SS, Wong PW, Malinow MR. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 1992; 12: 279-98.
6. Miner SE, Evroski J, Cole DE. Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clin Biochem 1997; 30: 189-201.
7. Menéndez A, Fernández-Britto JE. Metabolismo de la homocisteína y su relación con la aterosclerosis. Rev Cubana Invest Biomed 1999; 18: 155.
8. Jaconsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998; 44: 1833-43.
9. Stamler JS, Osborne JA, Jaraki O, Simon DI, Welch GN, Upchurch GR, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 9: 308-18.
10. Kronenberg F. Homocysteine, lipoprotein a and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease. Curr Opin Nephrol Hypertens 1998; 7: 271-8.
11. Kang SS, Wong PW, Susmano A. Thermolabile methylentetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536.
12. Frost P, Blom HJ, Milos R. A candidate genetic risk factor for vascular disease: a common mutation in MTHFR. Nat Genet 1995; 10: 111.
13. Gallagher PM, Meleady R, Shields DC. Homocysteine and risk of premature heart disease: evidence for a common gene mutation. Circulation 1996; 94: 2154.
14. Guttormsen AB, Ueland PM, Nesthus I. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia. J Clin Invest 1996; 98: 2174.
15. Harmon DL, Woodside JV, Yarnell JW. The common thermolabile variant MTHFR is a major determinant of mild hiperhomocysteinemia. QJM 1996; 89: 571.
16. Selhub J, Jacques PF, Wilson PN. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693.
17. Den Heijer M, Brower IA, Bos GH. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998; 18: 356.
18. Nedrebo BG, Ericsson UB, Nygard O. Plasma total homocysteina levels in hyperthiroid and hypothiroid patients. Metabolism 1998; 47: 89-93.
19. Smulders YM, De Man AME, Stehouwer CD. Trimethoprim and fasting plasma homocysteine. Lancet 1998; 352: 1827
20. Refsum H, Ueland PM, Kvinnsland S. Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res 1986; 46: 5385.
21. Nygard O, Refsun M, Ueland PM. Coffee consumption and plasma total homocysteine, the Hordaland homocysteine study. Am J Clin Nutr 1997; 65: 136.
22. Falk E, Zhou J, Moller J. Homocysteine and atherothrombosis. Lipids 2001; 36 (Suppl): 3-11.
23. McCully KS. Vascular pathology of homocysteinemia implications for the patogenesis of atherosclerosis. Am J Pathol 1969; 56: 11.
24. Harker LA. Homocysteine induced artheriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731.
25. Yoo JH, Lee SC. Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001;158:425.
26. Welch GN, Upchurch GR, Farivar RS. Homocysteine induced nitric oxide production in vascular smooth muscle cells by NF-Kappa beta dependent transcripcional activation of NOS2. Proc Am Assoc Physicians 1998; 110: 22.
27. Tyagi SC. Homocysteine redox receptor and regulation extracellular matrix components in vascular cells. Am J Physiol 1998; 274: 396.
28. Al-Obaidi MK, Philippou H, Stubbs PJ, Adami A, Amersey R, Noble MM, et al. Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Circulation 2000; 101: 372.
29. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhaces thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992;79:2930.
30. Poddar R, Sivasubramanian N, DiBello PM. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001; 103: 2717.
31. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures: possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 1997; 272: 1935-42.
32. Christen WG, Ajavi UA, Glyn RJ, Hennekens CH. Blood levels of homocysteine and increased risk of cardiovascular disease: casual or casual? Arch Intern Med 2000; 160: 422.
33. Stampfer MJ, Malinow MR, Willett WC. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877.
34. Schwartz SM, Siscovick DS, Malinow R. Myocardial infarction in young women in relation to plasma homocysteine, folate, and a common variant in the MTHFR gene. Circulation 1997; 96: 412.
35. Cleophas TJ, Hornstra N, Van Hoogstraten B, Van der Meulen J. Homocysteine, a risk factor for coronary artery disease or not? A meta-analysis. Am J Cardiol 2000; 86: 1005.
36. Fallon UB, Wilwood P, Ben-Shlomo Y, Ubbink JB, Greenwood R, Smith GD. Homocysteine and ischemic stroke in men. The Caerphilly Study. J Epidemiol Community Health 2001; 55: 91.
37. Knet P, Reumanen A, Alfthan G. Hyperhomocysteine: a risk factor or a consequence of coronary heart disease? Arch Intern Med 2001; 161: 1589.
38. Ueland M, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72: 324-32.
39. Stehower CD, Weijemberg HP, Van den Berg H. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10 years follow up. Arterioscler Thromb Vasc Biol 1998; 18: 1895.
40. Clarke R, Collins MB, Lewington S, Donald A, Alfthan G, Tuomielto J, et al. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 2002; 288: 2015.
41. Al-Obaidi MK, Stubbs PJ, Collinson P. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1217.
42. Den Heijer M, Koster T, Blom HJ. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. MEJM 1998; 334: 759.
43. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 759.
44. Ridker PM, Mennekens CH, Selhub J. Interrelation of hyperhomocysteinemia, factor V Leiden and risk of thromboembolism. Circulation 1997; 95: 1777.
45. Quere I, Perneger TV, Zittoum J. Red blood cells methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case control study. Lancet 2002; 359: 747.
46. Kang SS, Passen EL, Ruggie N. Thermolabile defect of methylentetrahydrofolate reductase mutation in coronary artery disease. Circulation 2001; 103: 2048.
47. Kosokabe T, Okumura K, Sone T. Relation of a common MTHFR mutation and plasma homocysteine with intimal hyperplasia after coronary stenting. Circulation 2001; 103: 2048.
48. Kluijmans LAJ, Kastelein JJ, Lindermans J. Thermolabile MTHFR in coronary artery disease. Circulation 1997; 96: 2573.
49. Verhoef P, Rimm EB, Hunter DJ. A common mutation in the MTHFR gene and risk or coronary heart disease: Results among US men. J Am Coll Cardiol 1998; 32: 353.
50. Brattström L, Wilcken DE, Ohrvik J. Common MTHFR gene mutation leads hyperhomocysteinemia but no to vascular disease: the results of a metaanalysis. Circulation 1998; 98: 2520.
51. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, et al. Homocysteine, polymorphism MTHFR 677 C→T, and risk of ischemic stroke: Results of a meta-analysis. Neurology 2002; 59: 529-36.
52. McQuillan BM, Beilby JP, Nidorf M. Hyperhomocysteinemia but not the C677T mutation of MTHFR is an independent risk determinate of carotid wall thickening. The Perth Carotid Ultrasound Disease Study (CUDAS). Circulation 1999; 99: 2383.
53. Streifler JY, Rosengberg N, Chetrit A, Eskaraev R, Sela BA, Darkik R, et al. Cerebrovascular events in patients with significant stenosis of carotid artery are associated with hyperhomocysteinemia and platelet antigen-1 polymorphism. Stroke 2001; 32: 2753.
54. Put NM, Van der Gabreels F, Setevends EM. A second common mutation in the MTHFR gene: an additional risk factor to neural tube defects? Am J Hum Genet 1998; 62: 1044-51.
55. Brattström L. Common mutation in the MTHFR gene no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation 1997; 96: 3805.
56. Tokgozoglu SL, Alikasi M, Unsal I. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate. Heart 1999; 81: 518-22.
57. O'Leary DH, Polak JF, Kronmal RA, Kittner SJ, Bond MG, Wolfson SK, et al. Distribution and correlates of sonographically detected artery disease in the Cardiovascular Health Study (CHS). Stroke 1992; 23: 1752-60.
58. Selhub J, Jacques PF, Bostom AG. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. NEJM 1995;332:286.
59. Malinow MR, Nieto FJ, Szklo M. Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults: the atherosclerotic risk in communities study. Circulation 1993; 87: 1107.
60. Ridker PM, Manson JE, Buring JE. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999; 281: 1817.
61. Tsai MY, Arnett DK, Eckfelatt JH, Williams RR, Ellison RC. Plasma homocysteine and its association with carotid intimal-medial wall thickness. NHLBI family heart study. Atherosclerosis 2000: 151: 519-24.
62. Adachi H, Hirai Y, Fujiura Y, Matsuoka H, Satoh A, Imaizumi T. Plasma homocysteine levels and atherosclerosis in Japan: epidemiological study by use of carotid US. Stroke 2002; 33: 2177-81.
63. Mueller T, Furtmueller B, Aigeisdofer J, Luft C, Poeiz W, Haltmayer M. Total serum homocysteine, a predictor of extracranial carotid artery stenosis in male patients with symptomatic peripheral arterial disease. Vasc Med 2001; 61: 163.
64. Sen S, Oppenheimer SA, Lima J, Cohen B. Risk factor for progression of aortic atheroma in stroke. Stroke 2002; 33: 930-5.
65. Boushey CJ, Beresford SAA, Omenn GS. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049.
66. Moller J, Nielsen GH, Tvedegaard KG. A meta analysis of cerebrovascular disease and hyperhomocysteinemia. Scand J lab Invest 2000; 60: 491.
67. Vila N, Deulofeu R, Chamorro A, Piera C. Plasma homocysteine level in patients with ischemic cerebral infarction. Med Clin 1998; 110: 605.
68. Howard VJ, Sides EG, Newman GC, Cohen SN, Howard G, Malinow R, et al. Changes in plasma homocysteine in the acute phase after stroke. Stroke 2002; 33: 473.
69. Meikejohn DJ, Vickens MA, Dykhusein R. Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke. Stroke 2001; 32: 57.
70. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle aged British men. Lancet 1995; 346: 1395.
71. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons. The Framingham Study. Ann Intern Med 1999; 131: 352.
72. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombosis events in systemic lupus erythematosus. Lancet 1996; 348: 1120-4.
73. Bots ML, Launer LJ, Lindermans J. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam study. J Intern Med 1997; 242: 339.
74. Alftham G, Pekkanen J, Jauhiainen M. Relation of serum homocysteine and lipoprotein a concentrations to atherosclerosis disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.
75. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willet WC, Stampfer MJ. A prospective study of plasma homocysteine to cerebral infarction and cerebral atherosclerosis. Stroke 1994; 25: 1924-30.
76. Shimuza H, Kiyohara Y, Kato I, Tanizaki Y, Ueno H, Kimura Y, et al. Plasma homocysteine concentrations and the risk of subtypes of cerebral infarction. The Hisayama study. Cerebrovasc Dis 2002; 13: 9.
77. Álvarez-Sabín J, Turon J, Montaner J, Malinow R, Codina A. Plasma homocysteine levels in patients with AIT. Med Clin 1999; 113: 531.
78. Ay H, Arsava EM, Tokgogzoglu SL, Ozer N, Saribas O. Hyperhomocysteinemia is associated with the presence of left atrial thrombus in patients with non-valvular atrial fibrillation. Stroke 2003; 34: 909.
79. Vermeer S, Van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Carke R, et al. Homocysteine, silent brain infarts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 2002; 51: 285.
80. Sachdev PS, Valenzuela HJ, Brodaty H, Wang XL, Looi J, Lorentz L, et al. Homocysteine as a risk factor for cognitive impairment in stroke patients. Stroke 2003; 15: 155.
81. Boysen G, Brander T, Christensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke. Stroke 2003; 34: 1258.
82. Tanne D, Haim M, Goldbourt U, Boylo V, Doolman R Adler Y, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 2003; 34: 632.
83. Del Ser T, Barba R, Herranz AS, Seijas V, López-Manglano C, Domingo J, et al. Hyperhomocysteinemia is a risk factor of secondary vascular events in stroke patients. Cerebrovasc Dis 2001; 12: 91-8.
84. Thambyrajah J, Landray MJ, Jones HJ. A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Cardiol 2001; 37: 1858.
85. Van de Griend R, Haas FJ, Biesma DH, Duran H, Meuwissen OJ, Banga JD. Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinemia in patients with premature arterial disease and their relatives. Atherosclerosis 1999; 143: 177.
86. Lentz SR, Piegors DJ, Malinow MR. Suppelementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. Circulation 2001; 101: 1006.
87. 6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002; 288: 973-9.
88. International Task Force for the prevention of Cardiovascular disease. Homocysteine and cardiovascular disease: recommendations of the international task force for the prevention of cardiovascular disease. Nutr Metab Cardiovasc Dis 1998; 8: 212-71.
89. Malinow MR, Boston AG, Krauss RM. Homocysteine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99: 178-82.
90. Jenest J, Audelin MC, Lonn E. Homocysteine: to screen and treat or to wait and see? CMAJ 2000; 163: 37-8.
91. 6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis vascular disease. J Cardiovasc Risk 1998; 5: 249-55.
92. The VITATOPS Trial Study Group. The VITATOPS Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischemic attack or stroke. Cerebrovasc Dis 2002; 13: 120.
93. Clarke R, Stansbie R. Homocysteine and cardiovascular risk. Am Clin Biochem 2001; 38: 626-32.